Gilead Sciences (XSGO:GILD) Total Stockholders Equity : $19,078 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Gilead Sciences Total Stockholders Equity?

Gilead Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $19,078 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Gilead Sciences's Book Value per Share for the quarter that ended in Mar. 2025 was $15.32. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Gilead Sciences's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Gilead Sciences Total Stockholders Equity Historical Data

The historical data trend for Gilead Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Total Stockholders Equity Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

18,202.00

21,069.00

21,240.00

22,833.00

19,330.00

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															17,539.00	18,281.00	18,474.00	19,330.00	19,078.00

Gilead Sciences (XSGO:GILD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Gilead Sciences's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(19078	-	0)	/	1245.000
	=	15.32

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Gilead Sciences's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	19078
	=	0.00

Gilead Sciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XSGO:GILD) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).